Adjuvant systemic therapy for older adults with early-stage breast cancer

Women's Health

Volumn 5, Issue 3, 2009, Pages 251-262

  Pal, Sumanta Kumar ^a   Mortimer, Joanne ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Bisphosphonate; Breast cancer; Chemotherapy; Endocrine therapy; Estrogen receptor; HER2; Progesterone receptor; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; METHOTREXATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG TOLERABILITY; ENDOMETRIUM CANCER; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; REVIEW; ADJUVANT CHEMOTHERAPY; AGE; AGED; AGING; ALGORITHM; BREAST TUMOR; CANCER DIAGNOSIS; DRUG EFFECT; FEMALE; GENETICS; META ANALYSIS; METHODOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGING; ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; RECEPTOR, ERBB-2; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 67651160734     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.17     Document Type: Review

References (68)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 58, 71-96 (2008).
2. Hutchins LF, Unger JM, Crowley JJ et al.: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
3. Quaglia A, Tavilla A, Shack L et al.: The cancer survival gap between elderly and middle-aged patients in Europe is widening. Eur. J. Cancer. DOI: 10.1016/j.ejca.2008.11.028 (2008)
4. Hind D, Wyld L, Reed MW: Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br. J. Cancer 96, 1025-1029 (2007).
5. Hughes KS, Schnaper LA, Berry D et al.: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med. 351, 971-977 (2004).
6. Lavelle K, Moran A, Howell A et al.: Older women with operable breast cancer are less likely to have surgery. Br. J. Surg. 94, 1209-1215 (2007).
7. Smith BD, Haffty BG, Hurria A et al.: Postmastectomy radiation and survival in older women with breast cancer. J. Clin. Oncol. 24, 4901-4907 (2006).
8. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
9. Muss HB, Woolf S, Berry D et al.: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293, 1073-1081 (2005).
10. Elkin EB, Hurria A, Mitra N et al.: Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J. Clin. Oncol. 24, 2757-2764 (2006).
11. Giordano SH, Duan Z, Kuo Y-F et al.: Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J. Clin. Oncol. 24, 2750-2756 (2006).
12. Fargeot P, Bonneterre J, Roche H et al.: Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J. Clin. Oncol. 22, 4674-4682 (2004).
13. Muss HB, Berry DL, Cirrincione C et al.: Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB/CTSU 49907. J. Clin. Oncol. 26 (2008).
14. Bajetta E, Procopio G, Celio L et al.: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J. Clin. Oncol. 23, 2155-2161 (2005).
15. Jones S, Holmes F, O'Shaughnessy J et al.: Extended follow-up and ana lysis by age of the US oncology adjuvant trial 9735: docetaxel/ cyclophosphamide is associated with an overall survival benefit compared with doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res. Treat. (2008).
16. Muss HB, Berry DA, Cirrincione C et al.: Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B experience. J. Clin. Oncol. 25, 3699-3704 (2007).
17. Patt DA, Duan Z, Fang S et al.: Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J. Clin. Oncol. 25, 3871-3876 (2007).
18. Colleoni M, Price KN, Castiglione-Gertsch M et al.: Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet 354, 130-131 (1999).
19. Smith TJ, Khatcheressian J, Lyman GH et al.: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 24, 3187-3205 (2006).
20. Gianni L, Herman EH, Lipshultz SE et al.: Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26, 3777-3784 (2008).
21. Doyle JJ, Neugut AI, Jacobson JS et al.: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol. 23, 8597-8605 (2005).
22. Giordano SH, Pinder M, Duan Z et al.: Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24(18S), 521 (2006).
23. Hurria A, Goldfarb S, Rosen C et al.: Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast. Cancer Res. Treat. 98, 343-348 (2006).
24. Raji MA, Kuo Y-F, Freeman JL et al.: Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. Arch. Intern. Med. 168, 2033-2040 (2008).
25. Owusu C, Lash TL, Silliman RA: Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J. 13, 374-382 (2007).
26. Owusu C, Buist DSM, Field TS et al.: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J. Clin. Oncol. 26, 549-555 (2008).
27. Fink AK, Gurwitz J, Rakowski W et al.: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor - positive breast cancer. J. Clin. Oncol. 22, 3309-3315 (2004).
28. Malek K, Fink AK, Thwin SS et al.: The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer. Med. Care 42, 700-706 (2004).
29. Forbes JF, Cuzick J, Buzdar A et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month ana lysis of the ATAC trial. Lancet Oncol. 9, 45-53 (2008).
30. Mouridsen HT, Giobbie-Hurder A, Mauriac L et al.: BIG 1-98: A randomized double-blind Phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Breast Cancer Res. Treat. (2009).
31. Crivellari D, Sun Z, Coates AS et al.: Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J. Clin. Oncol. 26, 1972-1979 (2008).
32. Fisher B, Dignam J, Bryant J et al.: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001).
33. Gray RG, Rea DW, Handley K et al.: aTTom (adjuvant tamoxifen - to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer - preliminary results. J. Clin. Oncol. 26 (2008).
34. Peto R, Davies C, on Behalf of the ATLAS Collaboration: ATLAS (Adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Breast Cancer Res. Treat. (2008).
35. Goss PE, Ingle JN; Martino S et al.: Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: national cancer institute of Canada clinical trials group MA.17. J. Clin. Oncol. 25, 2006-2011 (2007).
36. Muss HB, Tu D, Ingle JN et al.: Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J. Clin. Oncol. 26, 1956-1964 (2008).
37. Buzdar A, Howell A, Cuzick J et al.: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety ana lysis of the ATAC trial. Lancet Oncol. 7, 633-643 (2006).
38. Chang J, Powles TJ, Ashley SE et al.: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann. Oncol. 7, 671-675 (1996).
39. Seeman E: Pathogenesis of bone fragility in women and men. Lancet 359, 1841-1850 (2002).
40. Hadji P, Body J-J, Aapro MS et al.: Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol. 19, 1407-1416 (2008).
41. Braithwaite RS, Chlebowski RT, Lau J et al.: Meta-ana lysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. 18, 937-947 (2003).
42. Qato DM, Alexander GC, Conti RM et al.: Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300, 2867-2878 (2008).
43. Goetz M, Knox S, Suman V et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
44. Rau T, Wuttke H, Michels LM et al.: Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin. Pharmacol. Ther. (2008).
45. Bijl MJ, Visser LE, Hofman A et al.: Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br. J. Clin. Pharmacol. 65, 558-564 (2008).
46. Stearns V, Johnson MD, Rae JM et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95, 1758-1764 (2003).
47. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst. 92, 550-556 (2000)
48. Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
49. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
50. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
51. Slamon D, Eiermann W, Robert N et al.: BCIRG 006: 2nd interim ana lysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Breast. Cancer Res. Treat. (2007).
52. Tan-Chiu E, Yothers G, Romond E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811-7819 (2005).
53. Perez EA, Suman VJ, Davidson NE et al.: Cardiac safety ana lysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 26, 1231-1238 (2008).
54. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
55. Ganry O, Baudoin C, Fardellone P et al.: Bone mass density and risk of breast cancer and survival in older women. Eur. J. Epidemiol. 19, 785-792 (2004).
56. Kritz-Silverstein D, Schneider D, Sandwell J: Breast cancer and bone mass in older women: is bone density prescreening for mammography useful? Osteoporos. Int. 17, 1196-1201 (2006).
57. Kerlikowske K, Shepherd J, Creasman J et al.: Are breast density and bone mineral density independent risk factors for breast cancer? J. Natl Cancer Inst. 97, 368-374 (2005).
58. Gnant M, Mlineritsch B, Schippinger W et al.: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12. J. Clin. Oncol. 26 (2008).
59. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
60. Albain K, Barlow W, Shak S et al.: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). Breast. Cancer Res. Treat. (2008).
61. Ozanne EM, Braithwaite D, Sepucha K et al.: Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J. Clin. Oncol. 27, 214-219 (2009).
62. Muss HB, Tu D, Ingle JN et al.: Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J. Clin. Oncol. 26, 1956-1964 (2008).
63. Wildiers H, Kunkler I, Biganzoli L et al.: Management of breast cancer in elderly individuals: recommendations of the international society of geriatric oncology. Lancet Onco. 8, 1101-1115 (2007).
64. Giordano SH, Hortobagyi GN, Kau S-WC et al.: Breast cancer treatment guidelines in older women. J. Clin. Oncol. 23, 783-791 (2005).
65. Owusu C, Lash T, Silliman R: Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res. Treat. 102, 227-236 (2007).
66. Hurria A, Gupta S, Zauderer M et al.: Developing a cancer-specific geriatric assessment. Cancer 104, 1998-2005 (2005).
67. Basso U, Bassi C, Falci C et al.: Does multidimensional geriatric assessment influence the prescription of adjuvant chemotherapy to elderly women with early breast cancer in a multivariate model? J. Clin. Oncol. 26 (2008).
68. Muss HB, Biganzoli L, Sargent DJ et al.: Adjuvant therapy in the elderly: making the right decision. J. Clin. Oncol. 25, 1870-1875 (2007).